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Keloidal scarring is a common and disfiguring skin problem yet its pathobiology is only 
partially understood and treatments remain sub-optimal (Glass 2017). To date, most 
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investigative studies have focused on established keloid lesions and the surrounding 
extracellular matrix (He et al., 2017). In contrast, here we explored transcriptomic 
alterations at an earlier time-point – during keloid formation. We studied keloid-prone 
individuals from pedigrees with an autosomal dominant history of keloids, as well as 
unaffected family members and healthy matched control subjects without any tendency 
to form keloids (see Supplementary Figure S1). All subjects were Taiwanese. 
Following institutional ethics approval and written informed consent, we 
performed 3mm punch biopsies of non-lesional upper outer buttock skin, followed by 
a further 4mm punch biopsy of the same site 6 weeks later (see Supplementary Table 
S1 and Supplementary Figure S2). For the study, biopsying buttock skin was deemed 
acceptable by both the participants and the ethics’ committee (see Supplementary 
material for further discussion thereof). The 6-week time-point was chosen based on 
feedback from the keloid-prone individuals as to when they were normally first aware 
that a keloid scar was developing. We undertook an integrative approach of RNA-Seq 
and miRNA expression analysis based on the two sets of skin biopsies (baseline and 6 
weeks later).  
The study involved 8 keloid-prone subjects and 6 healthy matched individuals. 
Each skin biopsy was immediately immersed in RNAlater (Thermo Fisher Scientific) 
and total RNA was isolated using the RNeasy Plus Universal kit (Qiagen), retaining 
miRNAs according to the manufacturer’s protocol. RNA samples were subjected to 
microarray analysis on Affymetrix GeneChip miRNA 4.0 arrays and total RNA-Seq 
analysis on Illumina pair-end sequencing (see Supplementary Materials). The RNA-
Seq raw data files and metadata have been deposited in the Sequence Read Archive 
(SRA ID: SRP137071) and the miRNA raw data and metadata in Gene Expression 
Omnibus (GEO ID: GSE113621). 
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A stepwise bioinformatics strategy was followed to identify differentially 
expressed miRNAs that may contribute to keloid pathogenesis (see Supplementary 
Materials and Supplementary Figure S3). This analysis highlighted 37 miRNAs that 
were differentially expressed in the keloid-prone subjects. Hierarchical clustering 
revealed two clusters which were upregulated 6 weeks after wounding (see 
Supplementary Figure S4).  
In parallel, differentially expression (DE) analysis was applied to the RNA-Seq 
data between keloid-prone and healthy subjects, which identified 8 genes at baseline 
and 47 genes at 6 weeks after wounding that were differentially expressed (adjusted P-
value < 0.05; see Supplementary Materials). Comparing healthy controls before and 
after wounding identified 2,215 differentially expressed genes, whereas the same 
analysis in the keloid-prone individuals identified 3,161 differentially expressed genes 
(see Supplementary Figure S5a). Of those genes, there were 513 genes specific to the 
healthy individuals and 1,449 genes specific to the keloid phenotype (see 
Supplementary Figure S5b). Hierarchical clustering of the differentially expressed 
genes specific to the keloid phenotype exhibited two distinct clusters showing changes 
in expression between baseline and 6 weeks after wounding (see Supplementary Figure 
S6). 
We further assessed pathway enrichment in the RNA-Seq data using the Gene 
Set Variation Analysis (GSVA) package (see Supplementary Figure S7) (Hänzelmann 
et al, 2013). For genes specific to the keloid phenotype, there were 101 differentially 
activated pathways between baseline and 6 weeks after wounding, while 24 pathways 
were found to be differentially activated for the genes that were specific to the healthy 
individuals (Figure 1, and see Supplementary Tables S2-S3). Of these, 22 pathways 
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that were specific to the keloid-prone individuals were present on the KEGG and 
Reactome pathway databases, which are manually curated and well-annotated.  
Of note, NOTCH signaling, MAPK signaling and Toll-like receptor pathways 
were found to be altered in keloid-prone individuals after wounding with a decrease in 
pathway activity. These pathways have already been suggested to play a role in keloid 
disease, and thus our analysis provides further evidence to support their involvement 
(Bagabir et al., 2011; Syed and Bayat., 2012; Wu et al., 2017). Moreover, DNA repair 
and p53 signaling pathways were also highlighted (Yamauchi et al., 2018). In addition, 
the analysis also identified altered regulation of insulin secretion and metabolic 
pathways (RNA, protein, fructose, mannose and glycerophospholipid metabolism) in 
keloid pathobiology. Of note, recent work has shown increased glycolytic metabolism 
in keloid fibroblasts suggesting that dysregulation of metabolic pathways such as 
glucose metabolism may contribute to keloid formation (Li et al., 2018).  
To identify the targetome of the differentially expressed miRNAs for each of 
the two clusters of the differentially expressed genes in keloid-prone individuals (see 
Supplementary Figures S4 and S6), we intersected the 37 miRNAs with the 1,449 genes 
that were specific to the keloid phenotype and that were identified from the analyses 
described above. As a result, there were 403 over-expressed mRNA-miRNA 
interactions for 24 DE miRNAs for cluster 1 and 635 down-regulated mRNA-miRNA 
interactions for 29 DE miRNAs. Figure 2a visualizes the networks derived from both 
up- and down-regulated putative targets that are specific to the keloid phenotype 6 
weeks after wounding.  
Next, to investigate the functional dynamic changes of the 1,449 DE genes that 
were involved in the targetome we conducted gene set enrichment analysis (GSEA) 
using the R package GAGE (Luo et al., 2009). This analysis identified MAPK signaling 
6 
 
pathway as the only gene set to be significantly dysregulated in the keloid prone 
subjects 6 weeks after wounding (see Supplementary Tables S4-S5). Notably, other 
published data have shown that inhibition of MAPK hinders invasive growth of keloid 
fibroblasts (Wu et al., 2017). 
Gene association network analysis was also performed to further classify the 
differentially expressed genes from the RNA-Seq dataset according to Reactome 
pathway terms and correlated expression values amongst them (Figure 2b, and see 
Supplementary Materials). This analysis demonstrated a divergent average expression 
profile of cytokine signaling genes between keloid-prone and healthy individuals 
during wound healing. Of note, interleukin (IL)-1α, IL-1β, IL-6, and TNF-α 
proinflammatory cytokines have been shown to be upregulated in keloid tissue (Ogawa 
et al., 2016). Differences in organelle biogenesis and metabolism were also highlighted, 
providing further support that dysregulation of metabolic pathways may contribute to 
keloid formation. 
In summary, our study provides a comprehensive and integrative analysis of the 
keloid transcriptome and miRNAome and highlights biological pathways that feature 
during keloid formation. Functional validation will be required to confirm these 
findings and determine mechanistic and potential therapeutic relevance. Similar studies 
at earlier time-points after wounding are also likely to add further insight to keloid 
biogenesis. 
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Figure legends 
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Figure 1. Pathway analysis during keloid formation. Hierarchical clustering of 
differentially activated pathways identified by the GSVA method for the differentially 
expressed genes specific to the healthy (top panel) and keloid-prone individuals 
(bottom panel). Green represents downregulated pathways and red represents 
overexpressed pathways. 
 
Figure 2. miRNA-mRNA targetome and gene association network analysis during 
keloid formation. (a) Targetome of DE miRNAs. Size of grey nodes indicates the p-
adjusted value for the differentially expressed miRNAs; the larger the node the more 
biological significant the miRNA is likely to have. Red nodes indicate upregulated 
genes while green nodes indicate downregulated genes in keloid subjects during keloid 
formation. (b) Gene association network during keloid formation (top panel). Genes 
are represented by colored nodes and are split into 27 clusters, sized by the number of 
genes in them. Genes in the same cluster are connected with black edges and genes that 
are connected across clusters with red edges. Average expression change in each cluster 
of the gene association network in keloid-prone and healthy individuals between 
baseline and 6 weeks after wounding (bottom panel). Each cluster is referenced by the 
x, y coordinate system. The x-axis represents time points, while the y-axis represents 
the average expression in each cluster. All expression levels are standardized and 
centered for plotting purposes.  
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Supplementary material 
 
Time series integrative analysis of RNA-Seq and miRNA expression data reveals 
key biologic wound healing pathways in keloid-prone individuals 
Alexandros Onoufriadis et al. 
 
 
 
 
 
Supplementary Figure S1. Pedigrees from whom keloid-prone individuals were 
recruited for this study. Study skin biopsies were obtained from keloid-prone 
individuals indicated with a K and controls with N. An additional 4 matched controls 
not contained in these pedigrees were also included in the study. F numbers depict 
internal pedigree reference numbers. 
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Supplementary Table S1. Demographics for keloid-prone and control samples 
 
 Sample ID Age (years)  Sex Main keloid-prone areas Duration (years)  
Keloid     
K-1 32 male bilateral arms, abdomen 10 
K-2 23 male bilateral mandibular area, chest 7 
K-3 28 female left arm 12 
K-4 23 male chest 5 
K-5 24 male back 12 
K-6 30 male chest, back  18 
K-7 57 female Left arm 44 
K-8 25 male chest 10 
     
Control     
N-1 24 male   
N-2 58 male   
N-3 28 male   
N-4 22 male   
N-5 31 male   
N-6 34 male   
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Supplementary Figure S2. Study design and keloid phenotype. (a) Illustration of 
established keloid lesions in the keloid-prone individuals who participated in the study. 
(b)  Skin biopsy protocol and sample preparation for non-lesional skin in these 
individuals and the control subjects. The upper outer buttock was selected as the biopsy 
site in all individuals (keloid-prone and controls). The second punch biopsy was taken 
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directly overlying the initial punch biopsy. Following the second biopsy, the biopsy site 
in the keloid-prone individuals was injected with intra-dermal triamcinolone (10mg/ml) 
to try to reduce the risk of subsequent keloid scarring at this site. Nevertheless, within 
3 months, 2 of 8 individuals went on to develop keloids at the biopsy site necessitating 
further intralesional triamcinolone treatment to reduce keloid size. None of the control 
subjects wound sites went on to form keloids. 
 
 
Limitations of the study model. 
 
The buttock is not a prototypic site for keloid formation. However, it was not deemed 
ethically acceptable to biopsy more typical keloid-prone sites such as the skin overlying 
the sternum or shoulders. Nor were such biopsy sites acceptable to the keloid-prone 
participants (or control subjects). Ethics’ committee approval also required us to try to 
avoid keloids forming after our second biopsies by injecting intra-lesional steroids to 
the biopsy sites, similar to what might be done in clinical practice in keloid-prone 
individual undergoing minor skin surgical procedures. The question therefore arises 
whether biopsying buttock skin is able to truly reflect the cellular pathology and events 
that typify what happens during “normal” keloid formation? The observation that two 
individuals in the study developed keloids at the biopsy site, despite the intra-lesional 
steroid injections, indicates that keloids - in keloid-prone individuals – can develop at 
this site, and that biopsying buttock skin may provide a useful and acceptable model 
for analyzing keloid biogenesis. Indeed, some of the other 6 keloid-prone individuals 
may also have gone on to develop keloids at the biopsy sites were it not for the injection 
of intra-lesional steroids, and thus undertaking subgroup analysis of those individuals 
who did or did not form keloids is not appropriate for this study. Nevertheless, it is 
important to reflect that our model for study may not precisely reflect events at other 
more typical keloid sites.  
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miRNA Expression Analysis 
miRNA expression values were quantile normalized using Robust Multi-array Average 
(RMA) package in R and differential expression analysis was applied in the dataset 
across four different groups of samples (between keloid-prone and non-prone subjects 
at baseline and 6 weeks after wounding). Principal component analysis (PCA) was used 
to assess the clustering of samples. The limma (Linear Models for Microarray and 
RNA-Seq Data) package embedded in R (http://www.r-project.org/) was used to select 
miRNAs whose mean expression level was significantly different between different 
experimental conditions and further generated a list of microRNAs with associated 
statistics (Ritchie et al., 2015). Population level control and one factor analysis were 
used and miRNAs with an absolute fold change greater than 1.5 and adjusted p-value 
< 0.05 were selected as candidates that have significantly different expression for each 
comparison.  
Initially, bioinformatics analysis identified 275 differentially expressed 
miRNAs in healthy individuals between baseline and 6 weeks after wounding, whereas 
400 differentially expressed miRNAs were identified in the keloid-prone individuals 
between the two time points (Supplementary Figure S3 – Step 1). Next, the intersection 
of mirTarBase and TargetScanDB databases was used to annotate the differential 
expressed miRNAs across the four different conditions with their predicted target 
genes, resulting in 129,477 common miRNA-mRNA interactions in the two databases 
and 333 unique miRNAs (Supplementary Figure S3 – Step 2). By cross-referencing the 
differentially expressed miRNAs with the unique miRNAs of the miRNA-mRNA 
interactions, we identified 91 miRNAs that differentiate the healthy individuals 
between the two time points and 122 miRNAs for the keloid-prone individuals. Of 
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those, there were 6 miRNAs specific to the healthy individuals and 37 miRNAs specific 
to the keloid-prone subjects (Supplementary Figure S3 – Step 3). 
 
 
Supplementary Figure S3. Stepwise differential expression profiling analysis of the 
miRNA expression data. 
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Supplementary Figure S4. Hierarchical clustering of the 37 unique differentially 
expressed miRNAs in the keloid phenotype, following cross-reference with the unique 
miRNAs of the miRNA-mRNA interaction databases. Two clusters discriminate 
miRNAs that exhibit an upregulation in keloid prone subjects 6 weeks after wounding. 
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RNA-Seq library preparation and sequencing 
Whole transcriptome RNA-Seq libraries were prepared on the Agilent Bravo liquid 
handling system using a modification of the Agilent Sureselect stranded RNA kit 
(Catalog 9691B). Briefly, ribosomal RNA was removed from 900ng of high quality 
RNA using the Ribozero Gold rRNA removal kit (Illumina, Cambridge cat 
MRZG12324) and ribodepletion was verified on a Bioanalyzer Pico RNA chip (Agilent 
catalog 5017-1513). Ribodepleted RNA was fragmented and reverse transcribed with 
random primers in the presence of Actinomycin D (Sigma) to inhibit antisense artifacts 
through DNA dependent DNA synthesis (Perocchi et al., 2007). Second strand was 
synthesized with dUTP, the ends of ds-cDNA were polished followed by adaptor 
ligation and PCR amplification in the presence of Uracil-DNA-Glycosylase (UDG) to 
selectively degrade the second strand. Libraries were bead purified using Ampure 
beads, fragment size confirmed on Agilent Tapestation D1000 Screentape and 
quantified with Qubit. Sequencing was conducted on HiSeq2500 and HiSeq3000 
(Illumina, Cambridge). 
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RNA-Seq Data Analysis 
Sequencing reads were aligned against the human genome sequence (hg38) using 
hisat2. Reads with a MAPQ (mapping quality) below 10 and PCR duplicate reads were 
removed with Samtools package. On average, 121 million reads per samples were 
obtained. The UCSC hg38 genome annotation was used to generate gene count tables 
for each sample using the GenomicAlignments library in R (Lawrence et al., 2013). 
Gene counts for the technical replicates were added together and data were normalized 
for library size correction using DESeq2. Principal Component Analysis (PCA) on the 
normalized gene counts was performed to ensure the homogeneity of the data and to 
exclude any potential batch effects among sequencing runs. Sample N3-2nd was 
removed because of outlier status. Following normalization, low-expressed genes with 
an average expression across all samples of less than 3 reads were removed. RNA 
differential expression (DE) analysis was performed with the glmmADMB package in 
R using a mixed effect generalized linear model with a random intercept for each patient 
from the negative binomial family (Fournier et al. 2012). 
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Supplementary Figure S5. (a) Differentially expressed genes across the different 
phenotypes before and after wounding. (b) Venn diagram reveals unique genes in the 
pairwise comparisons. 
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Supplementary Figure S6. Hierarchical clustering reveals two distinct clusters with 
expression differences between baseline and 6 weeks after wounding for the 1449 
keloid-specific genes. 
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Pathway Enrichment Analysis 
Gene Set Variation Analysis (GSVA) of the DE RNA-Seq data was performed in R 
using the C2 collection of curated gene sets that form part of the Molecular Signatures 
Database (MSigDB) version 3.0. GSVA transforms the data from a gene-by-sample 
matrix to a gene set-by-sample matrix by performing a change in coordinate systems, 
and therefore allowing for the evaluation of pathway enrichment for each sample 
(Supplementary Figure S7). A stringent cut-off (adjPvalueCutoff = 0.001) was 
employed to attain high level of statistical and biologic significance. 
      
 
 
Supplementary Figure S7. Schematic representation of the GSVA method showing 
the conversion of a gene-by-sample matrix to a gene set-by-sample matrix. 
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Supplementary Table S2. Differentially regulated pathways identified by the GSVA 
method for the 513 genes that were specific to the healthy individuals. 
 
Gene Sets (according to MSigDB C2 collection) logFC* AveExpr t P.Value adj.P.Val B 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN 1.183782 -0.02015 10.05267 4.44E-09 1.34E-06 11.09738 
BROWNE_HCMV_INFECTION_4HR_DN 1.169318 -0.00657 9.712124 7.75E-09 1.34E-06 10.55167 
NIKOLSKY_BREAST_CANCER_16P13_AMPLICON -1.03877 -0.00717 -8.64669 4.84E-08 5.58E-06 8.747387 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP 1.099515 0.011772 8.319773 8.73E-08 7.55E-06 8.163094 
RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP 0.849148 -0.00568 7.090821 9.12E-07 5.83E-05 5.832659 
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP 0.882856 -0.00633 7.038979 1.01E-06 5.83E-05 5.729668 
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP -0.83025 -0.00941 -6.92105 1.28E-06 6.33E-05 5.493992 
ELVIDGE_HYPOXIA_DN -0.98957 0.02289 -6.44432 3.40E-06 0.000131 4.521731 
CAIRO_HEPATOBLASTOMA_UP 0.807335 -0.02311 6.441304 3.42E-06 0.000131 4.515492 
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN 0.83585 0.019098 6.045407 7.86E-06 0.000272 3.684998 
BROWNE_HCMV_INFECTION_24HR_DN 0.887437 0.02928 5.770285 1.42E-05 0.000432 3.096397 
JISON_SICKLE_CELL_DISEASE_UP 0.785883 0.036665 5.725194 1.56E-05 0.000432 2.999086 
KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM 0.739191 -0.04794 5.685418 1.71E-05 0.000432 2.913056 
REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS -0.80359 -0.01124 -5.67427 1.75E-05 0.000432 2.888906 
CHEN_HOXA5_TARGETS_9HR_UP 0.799507 0.043153 5.596677 2.07E-05 0.000477 2.720493 
KEGG_ENDOCYTOSIS -0.85191 -0.01476 -5.35382 3.53E-05 0.000763 2.189317 
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN 0.667295 0.014279 5.278539 4.17E-05 0.000828 2.0235 
LEE_NEURAL_CREST_STEM_CELL_DN 0.723797 0.037029 5.263428 4.31E-05 0.000828 1.990152 
KIM_WT1_TARGETS_UP 0.664411 0.002188 5.193463 5.03E-05 0.000904 1.835495 
HOSHIDA_LIVER_CANCER_SURVIVAL_DN -0.70418 -0.01376 -5.14383 5.62E-05 0.000904 1.725532 
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN -0.72564 0.014966 -5.13046 5.79E-05 0.000904 1.69588 
KIM_WT1_TARGETS_DN 0.607918 -0.02711 5.121005 5.92E-05 0.000904 1.67489 
NUYTTEN_NIPP1_TARGETS_UP 0.663922 0.014935 5.103511 6.15E-05 0.000904 1.636052 
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP 0.731321 0.053744 5.095033 6.27E-05 0.000904 1.617221 
 
* FC refers to the differential expression between control samples at day 42 vs Day 0  
For MSigDB collections: 
http://software.broadinstitute.org/gsea/msigdb/collections.jsp 
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Supplementary Table S3. Differentially regulated pathways identified by the GSVA 
method for the 1449 genes that were specific to the keloid-prone individuals.  
 
Gene Sets* (according to MSigDB C2 collection) logFC** AveExpr t P.Value adj.P.Val B 
KOBAYASHI_EGFR_SIGNALING_24HR_UP 1.000138 -0.01189 10.55765 3.62E-10 1.44E-07 13.44671 
LAU_APOPTOSIS_CDKN2A_UP 0.993493 -0.01853 10.86145 2.12E-10 1.44E-07 13.96596 
REACTOME_DNA_REPAIR -0.94955 -0.00332 -10.177 7.20E-10 1.79E-07 12.77967 
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP 1.058949 -0.01511 10.05451 9.01E-10 1.79E-07 12.561 
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP -1.0039 0.014287 -9.87279 1.26E-09 2.01E-07 12.23302 
KEGG_NOTCH_SIGNALING_PATHWAY -0.98173 0.043333 -9.71578 1.69E-09 2.14E-07 11.94611 
SABATES_COLORECTAL_ADENOMA_DN 0.850325 -0.00294 9.658409 1.89E-09 2.14E-07 11.84046 
NIKOLSKY_BREAST_CANCER_16P13_AMPLICON -0.97521 0.013771 -9.24433 4.17E-09 4.14E-07 11.0647 
KEGG_MAPK_SIGNALING_PATHWAY -0.82233 -0.02534 -8.96403 7.22E-09 4.73E-07 10.52623 
MAYBURD_RESPONSE_TO_L663536_DN -0.90647 0.013188 -9.02439 6.41E-09 4.73E-07 10.64311 
REACTOME_INNATE_IMMUNITY_SIGNALING -0.9752 0.012237 -8.92926 7.74E-09 4.73E-07 10.45869 
REACTOME_TOLL_LIKE_RECEPTOR_3_CASCADE -0.9752 0.012237 -8.92926 7.74E-09 4.73E-07 10.45869 
REACTOME_TOLL_RECEPTOR_CASCADES -0.9752 0.012237 -8.92926 7.74E-09 4.73E-07 10.45869 
BROWNE_HCMV_INFECTION_6HR_UP -0.98553 -0.019 -8.75839 1.09E-08 6.18E-07 10.12426 
SCHUHMACHER_MYC_TARGETS_UP -0.97424 0.001571 -8.59373 1.52E-08 8.03E-07 9.798136 
ODONNELL_TFRC_TARGETS_DN -0.80427 -0.02557 -8.5514 1.65E-08 8.20E-07 9.713684 
REACTOME_GLUCOSE_REGULATION_OF_INSULIN_SECRETION -0.90846 -0.00318 -8.25928 3.01E-08 1.41E-06 9.123977 
MISSIAGLIA_REGULATED_BY_METHYLATION_DN -0.90167 0.010577 -8.10898 4.11E-08 1.81E-06 8.815857 
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM -0.90756 -0.00807 -8.05696 4.58E-08 1.87E-06 8.70848 
RODRIGUES_DCC_TARGETS_DN 0.716196 0.005976 8.043151 4.71E-08 1.87E-06 8.679911 
CHENG_IMPRINTED_BY_ESTRADIOL 1.043827 0.008587 7.946755 5.78E-08 2.01E-06 8.479728 
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN -0.76098 -0.01989 -7.94314 5.82E-08 2.01E-06 8.472189 
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP -0.76098 -0.01989 -7.94314 5.82E-08 2.01E-06 8.472189 
PODAR_RESPONSE_TO_ADAPHOSTIN_UP 0.729459 0.013285 7.854346 7.02E-08 2.33E-06 8.286596 
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN -0.77226 -0.04696 -7.81695 7.60E-08 2.42E-06 8.208096 
WEST_ADRENOCORTICAL_TUMOR_DN 0.563721 -0.02509 7.765676 8.48E-08 2.59E-06 8.100147 
REACTOME_INTEGRATION_OF_ENERGY_METABOLISM -0.81238 -0.01477 -7.70488 9.66E-08 2.84E-06 7.971668 
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN 0.848678 0.037433 7.430023 1.75E-07 4.97E-06 7.38439 
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_8G -0.88049 -0.00325 -7.35071 2.08E-07 5.68E-06 7.212967 
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN 0.807922 0.004595 7.33706 2.14E-07 5.68E-06 7.183385 
BENPORATH_ES_1 -0.59604 0.00292 -7.20347 2.88E-07 7.31E-06 6.892458 
NGUYEN_NOTCH1_TARGETS_DN -0.90911 0.010124 -7.19338 2.94E-07 7.31E-06 6.870381 
KAUFFMANN_DNA_REPLICATION_GENES -0.74468 0.029854 -7.05786 3.98E-07 8.95E-06 6.572588 
PUJANA_BREAST_CANCER_LIT_INT_NETWORK -0.71923 0.027218 -7.06725 3.89E-07 8.95E-06 6.5933 
REACTOME_REGULATION_OF_INSULIN_SECRETION -0.8035 -0.00883 -7.083 3.76E-07 8.95E-06 6.628031 
WEI_MIR34A_TARGETS -0.73811 0.010186 -7.04957 4.05E-07 8.95E-06 6.554288 
FIRESTEIN_PROLIFERATION -0.70045 0.025921 -7.01333 4.39E-07 9.19E-06 6.474208 
REACTOME_AXON_GUIDANCE -0.65862 -0.02215 -7.01493 4.38E-07 9.19E-06 6.477755 
VECCHI_GASTRIC_CANCER_EARLY_UP -0.61891 0.004229 -6.95025 5.06E-07 1.03E-05 6.334388 
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN 0.731221 -0.03316 6.890709 5.78E-07 1.15E-05 6.201912 
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ASTON_MAJOR_DEPRESSIVE_DISORDER_DN -0.63798 0.009268 -6.86316 6.15E-07 1.19E-05 6.140469 
RUIZ_TNC_TARGETS_DN -0.72356 0.005279 -6.81771 6.82E-07 1.29E-05 6.038882 
LINDGREN_BLADDER_CANCER_CLUSTER_1_DN -0.60063 -0.00917 -6.70501 8.80E-07 1.63E-05 5.785799 
SONG_TARGETS_OF_IE86_CMV_PROTEIN -0.82487 0.006249 -6.63537 1.03E-06 1.86E-05 5.628616 
PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN -0.67083 0.008931 -6.57148 1.19E-06 2.11E-05 5.483868 
VERHAAK_AML_WITH_NPM1_MUTATED_UP -0.60631 -0.02712 -6.51353 1.36E-06 2.36E-05 5.352154 
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_UP -0.68774 -0.00684 -6.42971 1.65E-06 2.80E-05 5.160903 
ROSS_AML_WITH_MLL_FUSIONS -0.85834 -0.01609 -6.31243 2.17E-06 3.60E-05 4.891892 
MASSARWEH_TAMOXIFEN_RESISTANCE_DN -0.59446 -0.02214 -6.25596 2.48E-06 4.02E-05 4.761778 
BENPORATH_PRC2_TARGETS -0.59854 -0.00483 -6.18979 2.89E-06 4.59E-05 4.608869 
REACTOME_BIOLOGICAL_OXIDATIONS 0.83103 0.009525 6.076609 3.77E-06 5.76E-05 4.346168 
REACTOME_PHASE_1_FUNCTIONALIZATION_OF_COMPOUNDS 0.83103 0.009525 6.076609 3.77E-06 5.76E-05 4.346168 
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP 0.510054 0.008107 6.033497 4.17E-06 6.25E-05 4.24574 
PROVENZANI_METASTASIS_DN -0.62241 -0.01288 -5.89672 5.76E-06 8.33E-05 3.92584 
WILCOX_PRESPONSE_TO_ROGESTERONE_UP 0.56312 0.022466 5.896236 5.77E-06 8.33E-05 3.924704 
KIM_WT1_TARGETS_DN 0.487331 -0.00753 5.836371 6.65E-06 9.27E-05 3.78409 
WONG_EMBRYONIC_STEM_CELL_CORE -0.57525 -0.00298 -5.83926 6.60E-06 9.27E-05 3.790888 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER -0.59493 0.005355 -5.81028 7.07E-06 9.69E-05 3.722708 
NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON 0.542719 0.041836 5.753972 8.09E-06 0.000109 3.589984 
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP 0.529805 0.002341 5.694893 9.31E-06 0.000121 3.450425 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP -0.66729 0.001285 -5.69535 9.30E-06 0.000121 3.451505 
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_DN -0.54356 0.013731 -5.68567 9.52E-06 0.000122 3.428609 
REACTOME_PLATELET_ACTIVATION 0.531231 -0.00775 5.656474 1.02E-05 0.000128 3.359502 
WINNEPENNINCKX_MELANOMA_METASTASIS_UP -0.59367 0.003779 -5.6538 1.03E-05 0.000128 3.353162 
REACTOME_METABOLISM_OF_PROTEINS 0.619841 0.033359 5.637109 1.07E-05 0.000131 3.313624 
WONG_ENDMETRIUM_CANCER_DN 0.75604 -0.01179 5.594264 1.18E-05 0.000143 3.212005 
KIM_WT1_TARGETS_12HR_UP -0.73606 -0.0411 -5.58202 1.22E-05 0.000145 3.182928 
KEGG_P53_SIGNALING_PATHWAY -0.57218 -0.01645 -5.52567 1.40E-05 0.000163 3.048993 
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5 -0.53053 -0.00105 -5.44002 1.72E-05 0.000196 2.844939 
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON 0.423658 0.000168 5.437157 1.73E-05 0.000196 2.838105 
FURUKAWA_DUSP6_TARGETS_PCI35_UP 0.54367 0.030323 5.40184 1.88E-05 0.000211 2.753797 
KEGG_GLYCOLYSIS_GLUCONEOGENESIS -0.605 0.001353 -5.32512 2.27E-05 0.00025 2.570352 
BILBAN_B_CLL_LPL_UP 0.630854 -0.016 5.307394 2.37E-05 0.000258 2.527907 
SABATES_COLORECTAL_ADENOMA_UP -0.6578 -0.00434 -5.23944 2.79E-05 0.0003 2.365021 
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN -0.67133 0.012634 -5.22906 2.86E-05 0.000303 2.340114 
DANG_MYC_TARGETS_UP -0.51829 -0.01363 -5.2015 3.06E-05 0.00032 2.273965 
REACTOME_CELL_JUNCTION_ORGANIZATION 0.513445 -0.00263 5.183873 3.20E-05 0.00033 2.231629 
WANG_SMARCE1_TARGETS_UP 0.627323 -0.02644 5.168352 3.32E-05 0.000338 2.19434 
MUELLER_PLURINET -0.55763 0.001991 -5.13036 3.64E-05 0.000366 2.103006 
KEGG_GLYCEROPHOSPHOLIPID_METABOLISM -0.61869 0.000997 -5.04602 4.47E-05 0.000444 1.900008 
REACTOME_METABOLISM_OF_RNA -0.60005 0.005003 -5.01078 4.87E-05 0.000478 1.815081 
BENPORATH_PROLIFERATION -0.4765 -0.01437 -4.9699 5.39E-05 0.000522 1.716523 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP -0.55114 0.020418 -4.94582 5.71E-05 0.000547 1.65845 
BENPORATH_EED_TARGETS -0.44183 -0.01099 -4.9147 6.17E-05 0.000584 1.583332 
REACTOME_MUSCLE_CONTRACTION 0.692889 -0.03459 4.908079 6.27E-05 0.000586 1.567363 
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LEE_DIFFERENTIATING_T_LYMPHOCYTE 0.633821 -0.01295 4.807104 8.03E-05 0.000742 1.323492 
SASSON_RESPONSE_TO_FORSKOLIN_DN 0.717346 0.029462 4.792682 8.32E-05 0.000752 1.288643 
SASSON_RESPONSE_TO_GONADOTROPHINS_DN 0.717346 0.029462 4.792682 8.32E-05 0.000752 1.288643 
REACTOME_FORMATION_OF_PLATELET_PLUG 0.415674 -0.00951 4.784697 8.48E-05 0.000758 1.269346 
GAL_LEUKEMIC_STEM_CELL_UP 0.497293 0.010221 4.780143 8.58E-05 0.000758 1.258339 
ELVIDGE_HYPOXIA_BY_DMOG_DN 0.617879 0.030054 4.766073 8.88E-05 0.000776 1.224333 
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN -0.40155 0.001137 -4.74356 9.39E-05 0.000811 1.169915 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP -0.60661 0.03329 -4.72037 9.94E-05 0.000849 1.113856 
BROWNE_HCMV_INFECTION_20HR_DN 0.685218 -0.02484 4.696294 0.000105 0.000892 1.055648 
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN -0.62102 -0.00789 -4.67604 0.000111 0.000927 1.00668 
BENPORATH_OCT4_TARGETS -0.42012 0.003577 -4.65044 0.000118 0.000938 0.944783 
RODWELL_AGING_KIDNEY_UP 0.458909 0.018979 4.661725 0.000115 0.000938 0.972064 
SMID_BREAST_CANCER_ERBB2_UP 0.580798 0.020327 4.658416 0.000116 0.000938 0.964063 
TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C -0.4227 -0.02818 -4.65284 0.000117 0.000938 0.950574 
YEGNASUBRAMANIAN_PROSTATE_CANCER -0.58234 -0.00018 -4.66109 0.000115 0.000938 0.970529 
REN_ALVEOLAR_RHABDOMYOSARCOMA_DN 0.401401 -0.01494 4.64276 0.00012 0.000947 0.926206 
 
* Gene sets present in the Reactome and KEGG databases are highlighted in yellow 
and orange respectively 
** FC refers to the differential expression between keloid samples at day 42 vs Day 0  
For MSigDB collections: 
http://software.broadinstitute.org/gsea/msigdb/collections.jsp  
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Supplementary Table S4. Differentially activated pathways identified by the GSEA 
method for the 1,449 genes that were specific to the keloid-prone individuals. 
 
  p.geomean stat.mean p.val q.val 
hsa04010 MAPK signaling pathway 0.10390259 -1.271314 0.00031 0.002787 
 
 
 
 
 
Supplementary Table S5. MAPK signaling pathway genes involved in the keloid 
interactome between the RNA-Seq and miRNA datasets. 
 
genes miRNA logfc.genes pval.genes p.adj.genes p.adj.miRNAs reg.genes gs ENSEMBL ID 
MAP2K1 hsa-miR-34c-5p -0.35476633 0.00024254 0.001315459 0.002911087 down 5604 ENSG00000169032 
MAP2K1 hsa-miR-424-5p -0.35476633 0.00024254 0.001315459 0.002641301 down 5604 ENSG00000169032 
MAP3K2 hsa-miR-106a-5p 0.39859529 0.00682168 0.023968285 0.012701839 up 10746 ENSG00000169967 
MAP3K2 hsa-miR-330-3p 0.39859529 0.00682168 0.023968285 0.009208344 up 10746 ENSG00000169967 
RASA1 hsa-miR-30c-5p -0.2833839 0.00019165 0.001060305 0.013428058 down 5921 ENSG00000145715 
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Gene Association Network Analysis 
Differentially expressed genes from the four comparisons with adjusted P-value of less 
than 0.05 were used to construct gene association networks. Briefly, differentially 
expressed genes were represented in the form of a graph - where two genes are 
associated (i.e. were connected by a line in the graph) if they shared a Reactome ID 
(Croft et al., 2014) and their expression profiles were correlated above absolute value 
of 0.6. In this network of 757 associated genes, clusters were detected using edge 
betweenness community detection algorithm (Newman et al., 2004), and implemented 
in igraph (Csardi et al., 2006) library in R. Each cluster is assigned a class label which 
is the most common Reactome term shared among the member genes of the respective 
cluster. The average expression profile of the genes in each cluster is calculated and 
plotted. 
  
30 
 
Supplementary References 
 
Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway 
knowledgebase. Nucleic Acids Res. 2014;42:D472-7.  
 
Csardi G, Nepusz T: The igraph software package for complex network research, 
InterJournal, Complex Systems 2006;1695.  
 
Fournier DA, Skaug HJ, Ancheta J, Ianelli J, Magnusson A, Maunder MN, et al. AD 
Model Builder: Using automatic differentiation for statistical inference of highly 
parameterized complex nonlinear models. Optim. Methods Softw. 2012;27:233–249. 
 
Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, et al. Software 
for computing and annotating genomic ranges. PLoS Comput Biol. 2013;9:e1003118. 
 
Newman ME, Girvan M. Finding and evaluating community structure in networks. 
Phys Rev E Stat Nonlin Soft Matter Phys. 2004;69:026113.  
 
Perocchi F, Xu Z, Clauder-Münster S, Steinmetz LM. Antisense artifacts in 
transcriptome microarray experiments are resolved by actinomycin D. Nucleic Acids 
Res. 2007;35:e128. 
 
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential 
expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 
2015;43:e47. 
